EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Scott Ullem; Chief Financial Officer, Corporate Vice President; Edwards Lifesciences Corp Daveen Chopra; Corporate Vice President - Surgical Structural Heart; Edwards Lifesciences Corp Larry Wood; ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion ...

Transcatheter Aortic Valve Replacement (TAVR ... Edwards’ CEO. Guidance: Edwards Lifesciences expects first quarter 2025 ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...